The Future of Genomics Medicine in Patient Care: Contributions from CHOP

基因组学医学在患者护理中的未来:CHOP 的贡献

基本信息

  • 批准号:
    9282527
  • 负责人:
  • 金额:
    $ 90.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-09-01 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP) has established a pediatric biorepository with over 60,000 children consented for access to electronic health records (EHRs) with regular updates, re-contact, and high-density genome-wide association (GWA) array data. For this project, we have proposed five specific aims reflecting the workgroup mechanism of the eMERGE consortium. These will build upon substantive Preliminary Data derived during eMERGE II, where a series of GWA, sequencing, pharmacogenomics (PGx), EHR integration, and return-of-results (RoR) projects helped establish a platform for translational and eMERGE III efforts. In the first of these aims, we propose to continue to expand the eMERGE phenotype library and we propose four lead phenotypes: obesity, epilepsy, intellectual disability, and autism, in which we have a strong record in discovery, integration, and translation. Under specific aim 2, we propose to leverage CAG's position as a world-leader in genomics research to characterize rare variants in 2,000 CAG patients, where we have already catalogued several hundred rare variants in the accompanying Appendix. Leveraging this resource and expertise at CAG and eMERGE, we propose to return actionable findings to a minimum of ~160 parents (Specific Aim 3). This effort will build upon our existing RoR platform established during eMERGE II that returned results to parents of 160 CHOP children with autism, and to several hundred individuals with PGx risk profiles. Our fourth aim is to evaluate the health impact, cost-effectiveness and ELSI implications of RoR, and we aim to longitudinally track all families to whom results are returned at four time-points, leveraging existing resources and surveys developed with pediatric eMERGE partners. Finally, we propose a massive expansion of our EHR integration, established under eMERGE II, which also provide and integrate education resources for patients and medical professionals across the eMERGE network. Ultimately, we anticipate that the immediate outcome of these efforts will be improved healthcare for patients at CHOP and expanding to the entire eMERGE network. Further, with our eMERGE partners, we aim to establish a blueprint for integrating genomics and EHR data on such a scale that it will have real potential to fundamentally change medical practice in the US.
 描述(由申请人提供):费城儿童医院(CHOP)的应用基因组学中心(CAG)已经建立了一个儿科生物储存库,超过60,000名儿童同意访问电子健康记录(EHR),定期更新,重新联系和高密度全基因组关联(GWA)阵列数据。对于这个项目,我们提出了五个具体目标,反映了eMERGE联盟的可持续发展机制。这些将建立在eMERGE II期间获得的实质性初步数据的基础上,其中一系列GWA,测序,药物基因组学(PGx),EHR整合和结果返回(RoR)项目帮助建立了一个转化和eMERGE III工作的平台。在第一个目标中,我们建议继续扩大eMERGE表型库,并提出四种主要表型:肥胖,癫痫,智力残疾和自闭症,我们在发现,整合和翻译方面有很好的记录。在具体目标2下,我们建议利用CAG作为基因组学研究世界领导者的地位来描述2,000名CAG患者的罕见变异,我们已经在附录中列出了数百种罕见变异。利用CAG和eMERGE的这一资源和专业知识,我们建议将可操作的结果返回给至少约160名家长(具体目标3)。这项工作将建立在我们在eMERGE II期间建立的现有RoR平台上,该平台将结果返回给160名患有自闭症的CHOP儿童的父母,以及数百名具有PGx风险特征的个体。我们的第四个目标是评估RoR的健康影响,成本效益和ELSI影响,我们的目标是纵向跟踪在四个时间点返回结果的所有家庭,利用现有资源和与儿科eMERGE合作伙伴开发的调查。最后,我们建议大规模扩展我们的EHR集成,在eMERGE II下建立,它还为eMERGE网络中的患者和医疗专业人员提供和集成教育资源。最终,我们预计这些努力的直接结果将是改善CHOP患者的医疗保健,并扩展到整个eMERGE网络。此外,与我们的eMERGE合作伙伴一起,我们的目标是建立一个整合基因组学和EHR数据的蓝图,其规模将具有从根本上改变美国医疗实践的真实的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hakon Hakonarson其他文献

Hakon Hakonarson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hakon Hakonarson', 18)}}的其他基金

Utilizing Polygenic Risk to Understand and Improve Outcomes: A Model For Overturning Health Disparities Through Minority-Enriched Genomics Healthcare
利用多基因风险来理解和改善结果:通过少数族裔丰富的基因组医疗保健推翻健康差异的模型
  • 批准号:
    10852564
  • 财政年份:
    2020
  • 资助金额:
    $ 90.63万
  • 项目类别:
Utilizing Polygenic Risk to Understand and Improve Outcomes: A Model For Overturning Health Disparities Through Minority-Enriched Genomics Healthcare
利用多基因风险来理解和改善结果:通过少数族裔丰富的基因组医疗保健推翻健康差异的模型
  • 批准号:
    10207724
  • 财政年份:
    2020
  • 资助金额:
    $ 90.63万
  • 项目类别:
The Future of Genomics Medicine in Patient Care: Contributions from CHOP
基因组学医学在患者护理中的未来:CHOP 的贡献
  • 批准号:
    9480307
  • 财政年份:
    2015
  • 资助金额:
    $ 90.63万
  • 项目类别:
The Future of Genomics Medicine in Patient Care: Contributions from CHOP
基因组学医学在患者护理中的未来:CHOP 的贡献
  • 批准号:
    9902001
  • 财政年份:
    2015
  • 资助金额:
    $ 90.63万
  • 项目类别:
The Future of Genomics Medicine in Patient Care: Contributions from CHOP
基因组学医学在患者护理中的未来:CHOP 的贡献
  • 批准号:
    9272117
  • 财政年份:
    2015
  • 资助金额:
    $ 90.63万
  • 项目类别:
Integrative Genomic Analyses of NMDA Receptor Pathway in Schizophrenia
精神分裂症 NMDA 受体通路的综合基因组分析
  • 批准号:
    8887155
  • 财政年份:
    2014
  • 资助金额:
    $ 90.63万
  • 项目类别:
3/3-Networks from Multidimensional Data for Schizophrenia and Related Disorders
3/3-来自精神分裂症和相关疾病多维数据的网络
  • 批准号:
    8501691
  • 财政年份:
    2012
  • 资助金额:
    $ 90.63万
  • 项目类别:
3/3-Networks from Multidimensional Data for Schizophrenia and Related Disorders
3/3-来自精神分裂症和相关疾病多维数据的网络
  • 批准号:
    8666061
  • 财政年份:
    2012
  • 资助金额:
    $ 90.63万
  • 项目类别:
Integrative Analysis of a GWAS Repository with EMRs from over 40,000 Children
对 GWAS 存储库与 40,000 多名儿童的 EMR 进行综合分析
  • 批准号:
    8514179
  • 财政年份:
    2012
  • 资助金额:
    $ 90.63万
  • 项目类别:
Integrative Analysis of a GWAS Repository with EMRs from over 40,000 Children
对 GWAS 存储库与 40,000 多名儿童的 EMR 进行综合分析
  • 批准号:
    8714381
  • 财政年份:
    2012
  • 资助金额:
    $ 90.63万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 90.63万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 90.63万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 90.63万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 90.63万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 90.63万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 90.63万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 90.63万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 90.63万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 90.63万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 90.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了